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Many debilitating neuropsychiatric and neurodegenerative disor-
ders are characterized by dopamine neurotransmitter dysregula-
tion. Monitoring subsecond dopamine release accurately and for
extended, clinically relevant timescales is a critical unmet need.
Especially valuable has been the development of electrochemical
fast-scan cyclic voltammetry implementing microsized carbon fiber
probe implants to record fast millisecond changes in dopamine
concentrations. Nevertheless, these well-established methods have
only been applied in primates with acutely (few hours) implanted
sensors. Neurochemical monitoring for long timescales is necessary to
improve diagnostic and therapeutic procedures for a wide range of
neurological disorders. Strategies for the chronic use of such sensors
have recently been established successfully in rodents, but new
infrastructures are needed to enable these strategies in primates.
Here we report an integrated neurochemical recording platform for
monitoring dopamine release from sensors chronically implanted in
deep brain structures of nonhuman primates for over 100 days,
together with results for behavior-related and stimulation-induced
dopamine release. From these chronically implanted probes, we
measured dopamine release from multiple sites in the striatum as
induced by behavioral performance and reward-related stimuli, by
direct stimulation, and by drug administration. We further developed
algorithms to automate detection of dopamine. These algorithms
could be used to track the effects of drugs on endogenous dopamine
neurotransmission, as well as to evaluate the long-term performance
of the chronically implanted sensors. Our chronic measurements
demonstrate the feasibility of measuring subsecond dopamine
release from deep brain circuits of awake, behaving primates in a
longitudinally reproducible manner.
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Dopamine neurotransmission is central to movement, moti-vation, and behavioral choice, along with other fundamental
behaviors (1, 2). Dysregulation of dopamine occurs in neuro-
psychiatric and neurologic disorders, including major depression
and Parkinson’s disease, impairing quality of life on a daily basis
(3, 4). Methods to allow accurate in vivo monitoring of dopamine
over extended timescales still have not been technically feasible
for primate brains, however, preventing the possibility of
assessing longitudinally the role of this neurotransmitter in
neurodegeneration and in the modulation of behavior.
Electrochemical fast-scan cyclic voltammetric (FSCV) tech-
niques have been shown to provide the optimal overall perfor-
mance for measuring dopamine neurotransmission at the
required fast timescales (milliseconds), sensitivity (nanomolar),
and chemical selectivity. Most such measurements, for technical
reasons, have been made from acutely implanted sensors that
provide a sensitive, minimally scarring interface. Chronic dopa-
mine recording systems have only begun to gain widespread use
(1, 2), and these methods have so far been applied only to ro-
dents. There is a great need to establish chronic measurements in
primates, for whom to date there are only few reports even of
acute dopamine measurements (5–8), with stable measurements
only for a few hours. The lack of chronic chemical sensors exists
despite great progress in the chronic electrophysiological re-
cording of spike and local field potential activity in behaving
nonhuman primates. Chronic measurements of dopamine will
aid in the identification of dopamine’s contribution to complex
behaviors degraded in human disorders, and to aid in testing the
clinical feasibility of treatments. Specific hurdles have included
large size, increasing the likelihood of tissue damage and probe
degradation, and the lack of infrastructure to allow physical
probe stability with on-demand movability.
Key challenges associated with the chronic use of FSCV derive
from the degraded capacity of long-implanted sensors to detect
dopamine due to both biologic and nonbiologic processes (9).
Neurochemical measurements made from acutely implanted
sensors produce minimal scarring due to brevity of contact (i.e.,
interface for several hours). Chronically implanted sensors,
however, produce persistent inflammation and scarring around
the sensor, which effectively produces a barrier between the
sensor and regions of neurochemical release. The carbon fiber
(CF) sensors used for FSCV semipermanently adsorb and ac-
cumulate films of proteins and byproducts of neurotransmitter
redox reactions (10), all of which are amplified by inflammation
(9). Implant size reductions have been critical to minimize
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brain response (9, 11) and to provide stable long-term use in
rodents (1, 2).
We have developed for nonhuman primate use sensors that
maintain the small rodent-scale footprints (1, 2) (7-μm tip di-
ameter), and we have implemented these in macaque monkeys
outfitted with a modular chamber interface (12) (Fig. 1 and Fig. S1),
allowing us to introduce CF sensors and to measure from these
probes both acutely and chronically. This modular implant platform
allowed us to make measurements of dopamine release from mul-
tiple sites in the striatum [the caudate nucleus (CN) and the puta-
men], as well as to identify and manipulate dopamine-containing
brain regions [substantia nigra pars compacta (SNc) and ventral
tegmental area (VTA)] that give rise to striatal dopamine-containing
inputs. We measured dopamine release in response to direct, con-
trollable electrical and pharmacologic stimulation, as well as
behavior-related and spontaneous dopamine release from the awake
monkeys for over months-long time periods. We characterized in
detail the performance of the chronically implanted sensors in acute
recordings as well to validate the identification of dopamine, and in
chronic recordings to test the capacity of our probes to measure
dopamine reliably for up to 170 d.
Results and Discussion
Following classic acute FSCV methods (1, 2), we measured
striatal dopamine release induced by direct electrical stimulation
of SNc-VTA cells and fibers and by systemic administration of a
dopamine-releasing drug (raclopride) to characterize perfor-
mance of chronically implanted sensors. Stimulation electrodes
were implanted to target the SNc-VTA as estimated by MRI
with our modular chamber (Fig. 1C and Fig. S1). Positions of the
stimulating electrodes were optimized by recording neuronal
spike activity predictive of reward (13) during behavioral per-
formance or by directly measuring stimulation-induced dopa-
mine from sensors acutely implanted in the striatum.
We first measured electrically stimulated striatal dopamine
release from chronically implanted sensors (Fig. 2 and Fig. S2).
The chemical identities of the measured electrochemical cur-
rents were evaluated by the shape of their cyclic voltammograms
(CVs), which demonstrated distinctive current peaks at the do-
pamine redox potentials of ∼−0.2 and 0.6 V (Fig. 2B). These
measurements were corroborated by administering raclopride
(dopamine D2 receptor antagonist), which increased the amount
of stimulation-evoked dopamine as measured from chronic
sensors (151% increase, P < 0.0005, six sites in four sessions, in
monkey M1) (Fig. 2 C–E). We confirmed that these effects could
also be obtained from acute sensors (149% increase, P = 0.028,
from four sites in four sessions in monkeys M1, M2, and M3)
(Fig. 2E and Fig. S3). The raclopride administration not only
increased stimulation-induced release, but could also be used to
increase spontaneous dopamine neurotransmission. This drug
was used to monitor and to modulate reproducibly endogenous
dopamine neurotransmission.
We developed an automated algorithm to identify these
transient changes in apparent dopamine concentration ([DA]a)
(Fig. 3) to detect such spontaneous dopamine release over extended
periods of recording from the chronically implanted sensors. The
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Fig. 1. Modular platform for chronic neurochemical measurements. (A) Mod-
ular chamber combines usage of acute and chronic systems and targets
multiple widespread brain regions. (B) Primate-implantable CF sensor. (Scale
bar, 100 μm.) (C) MRI of chamber grid and targeted striatal sites (purple).
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Fig. 2. Chronic measurements of dopamine release evoked by electrical
stimulation in monkey M1. (A) Electrical stimulation-evoked dopamine
measured on postimplant day 61 (probe cn1) in M1. (B) CV conferring do-
pamine neurochemical identity of measurement in A. (C) Stimulation-in-
duced dopamine oxidation current over time recorded from two electrodes
(cn1 and cn2) on postimplant day 64 in M1. Raclopride (Rac; arrowhead)
increases dopamine release. (D) Average peak stimulation-evoked dopamine
measured from chronically implanted sensors (cn1–3) before and after
raclopride drug treatment on postimplant days 61, 63, 64, and 106 in M1. Error
bars represent SD. (E) Percent increase of stimulated-evoked dopamine follow-
ing drug treatment for chronic (from five sites in M1, see Table S1) and acute
measurements (from four sites in M1, M2, and M3). Error bars represent SEM.
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boosting effects of raclopride were reliably tracked on sponta-
neous dopamine release with sensors implanted for over 4 mo
(monkeys M1 and M2) (Fig. 4, Fig. S4, and Table S1), including
tracking from multiple sites synchronously (Fig. S5). An increase
in the rate of dopamine neurotransmission was observed fol-
lowing raclopride treatment from the chronic sensors (average
change of 102% from 7 increases and 1 decrease in M1 and
11 increases and 4 decreases in M2, P = 0.0183) (Fig. 4 and Table
S1). Nonsignificant changes in dopamine concentration were de-
tected after raclopride (average increase of 5.8 nM in peak dopa-
mine after treatment across 23 measurement sites, P = 0.26) (Fig.
4). We simultaneously monitored these types of changes as they
occurred across multiple widely distributed regions across the CN
and putamen in M2 (Fig. S5). All of these chronically measured
drug-modulated dopamine dynamics could be confirmed with
acute measurements made in separate sessions (Fig. S4).
We tested whether the chronic sensors could be used to
measure striatal dopamine changes in response to rewarding (1,
2, 13) (Fig. 5 A–C) or surprising (14, 15) (Fig. 5D) stimuli. This
goal was achieved with monkey M2 in 19 recording sessions and
in M1 in 4 recording sessions made with sensors chronically
implanted over 4–5 mo. We detected reproducible patterns of
dopamine changes as M2 performed a reward-biased visual
saccade task [also referred to as the one-direction reward (1DR)
task] (16), which required the animal to fixate a central fixation
point and then, once it was extinguished, to make leftward or
rightward saccadic eye movements to a single peripherally illu-
minated target to receive, in different trials, small or large liquid
rewards (Fig. 5 E and F and Figs. S6 and S7). Larger dopamine
concentration changes were detected in trials that were associ-
ated with larger liquid rewards (Fig. 5 E–G), a result aligned with
the results of electrophysiological recording of the spike activity
of striatal neurons during similar motivational tasks in macaques
(17). These single-session chronic implant measurements compared
favorably with those that we recorded with acutely implanted
sensors (Fig. S6).
Direct measurements of behaviorally important neurochemicals
have been rare in primates and have only been made from acutely
implanted sensors. Here we show the feasibility of these long-term
recordings. The chronic dopamine monitoring methods that we
introduce here were validated with direct stimulation, pharma-
cologic, and behavioral protocols. The introduction of such long
time-scale recordings of dopamine release and their applications
in monitoring behaviorally encoded and drug-modulated dopa-
mine neurotransmission should open up the possibility of mea-
suring dopamine dynamics during performance of complex tasks,
a critical step toward understanding how dopamine signaling
evolves during learning and motivationally influenced behaviors.
As a prototype of such experiments, we used the 1DR task, well
known as a task in which spike activity related to motivation can
be interrogated (16). We show that in the same task that triggers
these electrophysiological signals, dopamine release is triggered.
The extended monitoring that was provided by our integrated
modular platform and algorithm could also be of great value in
clinical settings. Such measurements could provide diagnostic
measures of disease state and could be used to directly modify
treatment schedules, including those for patients already implan-
ted with deep brain stimulation devices, such as those implemented
for Parkinson’s disease therapy. These chronic measurements
could simplify procedures for assessing the functional integrity of
implanted sensors without the need for additional implants to
stimulate directly the release of dopamine. Such procedures are
impractical and risky in primates. The chronic implants could
further supplant use of the stiffer stimulation electrodes used with
conventional FSCV, which can physically shift position over time
(18), resulting in varying the amount of stimulated striatal dopa-
mine. Dopamine is heterogeneously released in the striatum (19–
21), and this spatial heterogeneity is related to the activity of af-
ferents in SNc/VTA. The multichannel probing capabilities in-
troduced here could be useful for elaborating topographical
midbrain projections to the striatum (22). The electrochemical
interface design and measurement protocols that we introduce
here for dopamine could be used broadly to detect chemical dy-
namics with long-term viability of neurochemical measurements.
Materials and Methods
Additional methods are provided in SI Materials and Methods.
Animals and Surgery. Two female rhesus macaque (Macaca mulatta) monkeys
(M1, 6.5 kg, and M2, 9.8 kg) were studied for acute and chronic recording
and one female rhesus macaque monkey (M3, 8.4 kg) was studied for acute
recording. Monkeys M1 and M3 were used for immunohistochemistry to
validate the location of implanted sensors and stimulation electrodes. All
experimental procedures were approved by the Committee on Animal Care
of the Massachusetts Institute of Technology. Monkeys were adapted to
transitions from cages to primate chairs using pole-and-collar and food or
liquid reinforcement. Animals were fitted with chronic chambers and grids
(12) in successive surgeries (chamber implantation and craniotomy) per-
formed under sterile conditions and with administration of sevoflurane
anesthesia preceded by intramuscular administration of ketamine (10 mg/kg)
and atropine (0.04 mg/kg). Postoperative maintenance included adminis-
tration of buprenorphine (0.15–0.2 mg/kg, subcutaneously), dexamethasone
(0.09–0.11 mg/kg, intramuscularly), ceftriaxone (1.2–1.6 mg/kg, intramuscu-
larly), and famotidine (0.4–0.51 mg/kg, intramuscularly).
Modular Chamber Implant Platforms. Chambers for monkeys M1 and M3 were
constructed as previously reported (12) and provided access for devices to be
implanted to brain structures either on a day-by-day basis or chronically.
Chambers were placed above the right hemisphere and in the coronal plane at
angles of 4°, 23°, and 5°, respectively, for M1, M2, and M3. In M2, a smaller,
single-hemisphere chamber (obtained from Gray Matter Research) was used
(Fig. 1). Grids were installed within the chambers and consisted of an array of
holes spaced 1-mm apart (40 × 30 or 24 × 20) having 1-mm center-to-center
distance and 0.48- or 0.64-mm diameters (Fig. S1A). Anatomical targeting was
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Fig. 3. Automated detection of dopamine. (A) Flow-chart diagram of de-
veloped algorithm used to identify local increases in dopamine (i.e., tran-
sients). Specific procedures are also detailed in Materials and Methods.
(B) Representative CVs (gray) automatically extracted from a recording in
ventral CN (cl6) of monkey M2 on postimplant day 124, demonstrating dis-
tinctive peaks at dopamine redox potentials and tight correlation to in vitro
dopamine standards (eight overlaid colored dashed traces).
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achieved by using structural 3.0T MRI (T1-weighted, 0.5-mm isotropic and T2-
weighted, 0.35-mm isotropic) to allow measurements relative to grid-hole co-
ordinates (Fig. S1B). Micromanipulators (MO-97A; Narishige) were mounted as
needed onto chambers to allow acute implantation of sensors or stimulation
electrodes (Fig. S1C). Microdrives (12) were permanently installed onto grids for
fixing chronic devices (Fig. S1D). In all monkeys (M1–M3), CF sensors were
acutely implanted into the CN and putamen to allow measurement of
stimulation-evoked dopamine release. In M1, six CF sensors were chronically
implanted into the CN and were fixed onto microdrive shuttles. In M2, 19 CF
sensors were chronically implanted into the CN and putamen. See SI Materials
and Methods for detailed implantation methods.
Electrochemical Recording. FSCV was performed using computer-controlled
instrumentation that allowed synchronous recording from four channels.
Each channel was connected to a CF sensor to apply a triangular voltage
waveform (−0.4 to 1.3 to −0.4 V at 400 V/s scan rate and 10-Hz cycle frequency)
and record generated current (see SI Materials and Methods for details).
Chemometric Analysis. The chemical identity of the measured electrochemical
signals as being dopamine was conferred by analysis of the CVs of the
background-subtracted data. Dopamine is known to produce current
changes at reduction and oxidation (redox) potentials of −0.2 and 0.6 V,
respectively, with the FSCV parameters applied in this work (2). Measured
CVs were further analyzed against in vitro dopamine standards (nine CVs)
generated in the flow cell to compute Pearson’s correlation coefficient, r.
Measured CVs were only identified as dopamine when r was greater than a
threshold, rt, as correlated to a dopamine standard and extraneous variance
(Q, or residual sum of squares) was below a tolerance level (Qα) during au-
tomated detection (see Automated Dopamine Detection).
Principal component regression (PCR) (19, 23) was used to convert
background-subtracted electrochemical current to projected changes in ap-
parent dopamine and also nondopamine currents (i.e., pH, background drift,
and movement) based on the principal components provided (i.e., 9 dopamine
standards, 8 pH standards, 11 background drift standards, and 36 movement
standards) (SI Materials and Methods). The dopamine standards can be seen
Vo
lta
ge
 (V
)
A
–0.4
1.3
–0.4
C
urrent (nA
)0
1.5
–0.8
C
urrent (nA
)0
2
–1
Tr
an
si
en
ts
 / 
m
in
Tr
an
si
en
ts
 / 
m
in
B
C
D
E
[DA]a nM (bins)
Predrug Postdrug
20 5Time (s)
10 nM
30 50Time (s) 50 0Time (s)
10 nM
0 20 40 60 80 100 120
0
5
10-8
100 P
-value
P-value
Rac
0 10 20 30 40 50 60 70 80 90 100
0
5
10-6
100 P
-value
Time (min)
P-value
Rac
Time (min)
5 15 25 35 45
0
0.5
5 15 25 35 45
5 15 25 35 45
0
0.5
5 15 25 35 45
[DA]a nM (bins)
61 63 64 106 126
Tr
an
si
en
ts
 / 
m
in
Predrug
Postdrug
Postimplant days [probe ID]
cn1 cn2 cn1 cn2 cn1 cn3 cn1 cn3
1.5
1
0.5
0
99 120 122 124 131
0
0.5
1.5
2.5
3.5
p1 cl1 cl3 cl5
Postimplant days [probe ID]
cl5b cl5b cl6 cl1 p6 cl5b p6 cl6 cl1 p4 cl6
F
Fig. 4. Chronic measurements of drug-modulated dopamine neurotransmission using automated detection algorithms. (A and B) Representative endogenous
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overlaid with in vivo measurements in Fig. 3B. In vivo dopamine concentration
changes were estimated based on in vitro calibrations. PCR-calculated projected
dopamine current was converted to apparent dopamine concentration change
(Δ[DA]a) by dividing it by the normalized sensitivity (19) (i.e., in vitro dopamine
sensitivity in nanoampere per nanomolar relative to background current in
nanoampere), and measured background current. CVs that could not be
accounted for as a physiological signal were automatically blanked out if Q ≥
Qα = 21. Only dopamine and pH standards were used to calculate the threshold,
Qα = 21, to ensure that current contributions that did not fall within expected
bounds of primary contributions with a confidence interval of 95% were re-
moved from analysis. Δ[DA]a traces were also nulled at points where CVs were
found to be highly correlated (r > 0.8) to movement standards.
The correlation threshold, rt = 0.8, was determined such that the hit rate
(probability that measured dopamine signals were accurately identified as do-
pamine) was 92%; the miss rate (probability that dopamine signals were not
identified) was 26%; and the rate of false positives or dopamine-resembling
CVs generated by movement of an electrode was 0. These rates were calculated
by measuring the distribution of r values for known dopamine signals (i.e., CVs
recorded in vitro) and for known movement signals (i.e., CVs recorded during
movement in vivo from probes that failed to detect any measurable dopamine)
(SI Materials and Methods). Movement-related nondopamine CVs can display
current changes at the redox potentials of dopamine and falsely correlate to
dopamine standards. In this work, monkeys were capable of making moderate
head movement as they were only fixed with a noninvasive side-clamp head
restrainer (24) rather than a movement-resistant head-post. The head restrainer
was chosen to reduce long-term risks associated with implanted head-posts.
Therefore, the aforementioned procedures were critical to thoroughly
remove signals that falsely allude to dopamine.
Automated Dopamine Detection. We automated detection of putative do-
pamine signals by constructing a template-matching algorithm (Fig. 3A). The
script iteratively generates background-subtracted data to search for CVs
correlated with dopamine standards with r > rt and Q < Qα. Background
subtraction occurs at intervals of 10 samples to create a searchable scan
window of data ±50 s from the background subtraction sample. In this
background-subtracted scan window, the script iteratively searches for
matching CVs at intervals of 0.5 s. When correlated samples are found, the
script converts the current to Δ[DA]a and searches for a time point (tmax) of local
maximum of dopamine change around the correlated CV time point. When this
local peak is found, the script searches for its rising and falling amplitudes hav-
ing >2–5 nM (or equivalently, four to five times the root mean square of a 1-s
period of the background signal) deflections around the Δ[DA]a at tmax. If a
peak ±0.7 s within the current peak has already been stored, or the current peak
does not display adequate decreases ±2 s around itself, the signal is omitted. The
CV at tmax is checked against standards (r > rt and Q < Qα). If CV(tmax) does not
meet the criteria for dopamine identification, CVs ± 1 s around the peak are
evaluated for dopamine identification. If these searches fail to provide amatching
dopamine CV, the signal is omitted; otherwise, tmax, Δ[DA]a, and CV(tmax) are
stored. This coarse detection scheme could be applied to continuous data (mi-
nutes to hours) recorded before and after drug modification to estimate changes
in frequency of endogenous dopamine release. The reliability of these procedures
is demonstrated in examples of detected CVs compared with in vitro standards, as
shown in Fig. 3B, and in their reproducible application in detecting them with
increased frequency following raclopride drug administration as corroborated in
both acute and chronic measurements (Fig. 4, Fig. S4, and Table S1). In the context
of this report, we define these local increases in apparent dopamine concentra-
tion as dopamine transients.
Drug Modulation. Raclopride (R-121, 0.05–0.1 mg/kg; Sigma-Aldrich) was ad-
ministered intramuscularly to the monkeys to amplify stimulation-induced do-
pamine or endogenous dopamine neurotransmission. This drug has been
shown to amplify electrically stimulated dopamine (20, 21) in rodents, as we
confirmed in the primate (Fig. 2 and Fig. S3). Raclopride selectively binds to
dopamine D2 receptors, and the inhibition of these receptors increases the
firing rate of dopamine-containing neurons that innervate striatum (25). Elec-
trochemical measurements in rodents demonstrate that raclopride induces in-
creased rates of endogenous dopamine release (26, 27). Raclopride produces
minimal effect on the levels of other neurotransmitters, such as noradrenaline
and serotonin (28). The drug is well-tolerated in humans at low doses, and its
major side effects are drowsiness and akathisia at higher doses (29). We noticed
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that monkeys sometimes appeared tired, fell asleep, or became restless, 30–
60min after administration. Raclopride was freshly prepared on the day of each
experiment by dissolving it in 0.9% saline (1 mg/mL).
Plots of dopamine transient rates (Figs. 4 C–F and Figs. S4 and S5) were
generated by binning the number of detected peak signals (see Automated
Dopamine Detection) for each minute of recording. Next, χ2 tests were per-
formed on the average baseline rate (period before raclopride administration)
and the average postraclopride rate using a sliding window of equal width to
the baseline period with 1-min increments following raclopride administration.
The P values generated by these sliding window measures of χ2 significance are
plotted as a dashed (significant increase) or dotted (significant decrease) curve
in the rate plots (Fig. 4 C and D and Figs. S4 and S5A) to display periods of
recording when the average transient rate significantly exceeds the baseline
rate (e.g., lower P value). Detected transients were then binned according to
their apparent peak dopamine concentration change to plot the average de-
tected rates according to their different ranges of dopamine concentration
change (Fig. 4 C and D and Figs. S4 and S5B). Average rates before and after
raclopride were calculated for each experimental session and were plotted to
demonstrate the reproducibility of the rate increases over many days (Fig. 4 E
and F). Average drug-induced changes in all sessions and subjects are reported
as mean increases and P values are generated using two-tailed t tests.
Reward-Biased Visual Saccades in 1DR Task. In one monkey (M2), we measured
dopamine neurotransmission during task performance in the 1DR behavioral
paradigm. In this eye-movement task, the monkey was trained to fixate on a
central cue for 1–2 s, then tomake a saccade toward a target that appears on the
left or the right of the screen, and then to fixate the target for 1–2 s to receive a
small reward or large reward. The left or right direction of the target was as-
sociated with a small or large reward in a given session and usually did not
change for a given day’s session, but could randomly change across sessions. A
meal shake (Ensure, Plus Nutrition Shake Vanilla) diluted with 50% water was
delivered through a spout in volumes of 0.3 and 2.8 mL for small and large
rewards, respectively. The probability of a large reward trial was set to 25%. The
intertrial interval (ITI) was set at a fixed value between 5 and 15 s for
each session.
Trials (reward time point ± ITI) were selected for dopamine analysis if the
trial retained at least 70% of its recorded CVs with Q < Qα. Periods displaying
extraneous CVs within each trial were automatically omitted during analysis
of dopamine concentration changes and blanked out (in gray) in the plotted
data (Figs. S6B and S7) (see Chemometric Analysis). Trial-by-trial changes in
dopamine (Figs. S6B and S7) were computed by background-subtraction to
the fixation period to evaluate differences in measured dopamine between
small and large reward trials (Fig. 5G). Maximum Δ[DA]a for each trial was
calculated by finding the peak Δ[DA]a at any time following fixation period
until 5-s postreward delivery. This large time window for finding maximum
Δ[DA]a was used to account for prolonged dynamics in task-related striatal
dopamine signals that we frequently observed in the measurements in
monkeys (Fig. 5 A–D) and that our group has previously observed in be-
having rodents (1), but have yet to fully interpret.
Changes in Dopamine Detection over Time. No standard criteria exist to assess
changes in dopamine measurement functionality of probes over time. Prior
investigations indicate that the CF’s intrinsic sensitivity to dopamine (nA/μM)
over chronic usage is not significantly altered as evaluated by post-explant
in vitro flow-cell measurements (2). These studies also demonstrated that
the dopamine signal originating from the nucleus accumbens, in response to
unexpected reward, does not significantly change over time as measured
from the chronically implanted probe. We attempted to characterize
changes in probe performance based on measurements of stimulated re-
lease. We observed a decrease in measured stimulated dopamine in monkey
M1 (Fig. 2). These decreases, however, could be a consequence of physical
migration of the stiff stimulating electrodes relative to targeted dopamine-
containing cell bodies. We also characterized the probes based on their
ability to detect correlated dopamine CVs. We observed a decrease in the
rate of detected dopamine in M1 across sessions in one of the probes (cn1)
(P < 0.003), but not in the other implanted probes (cn2 and cn3) (Fig. 4E).
Three of the implanted probes in M2 showed increase across sessions (cl1,
p6, and cl6) (P < 0.05), whereas one of the probes did not show significant
change (Fig. 4F).
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